Brokerages Set Solventum Corporation (NYSE:SOLV) Target Price at $90.64

Solventum Corporation (NYSE:SOLV) has been assigned an average recommendation of “Hold” from the thirteen brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $90.6364.

A number of analysts have issued reports on the company. Wells Fargo & Company raised Solventum to a “hold” rating in a research report on Wednesday, March 18th. Stifel Nicolaus lifted their price target on Solventum from $88.00 to $105.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Wall Street Zen cut Solventum from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a research report on Tuesday, January 27th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Solventum in a research report on Wednesday, December 17th.

Insider Buying and Selling at Solventum

In related news, Director Amy Mcbride Wendell purchased 1,475 shares of Solventum stock in a transaction dated Tuesday, March 10th. The stock was bought at an average cost of $68.03 per share, for a total transaction of $100,344.25. Following the completion of the transaction, the director owned 5,039 shares in the company, valued at $342,803.17. This trade represents a 41.39% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.24% of the company’s stock.

Hedge Funds Weigh In On Solventum

Hedge funds have recently made changes to their positions in the stock. Nordea Investment Management AB lifted its stake in Solventum by 3.5% during the third quarter. Nordea Investment Management AB now owns 758,847 shares of the company’s stock worth $54,880,000 after purchasing an additional 25,987 shares during the last quarter. LSV Asset Management lifted its stake in Solventum by 364.5% during the third quarter. LSV Asset Management now owns 35,122 shares of the company’s stock worth $2,564,000 after purchasing an additional 27,561 shares during the last quarter. Davis Selected Advisers lifted its stake in Solventum by 0.5% during the third quarter. Davis Selected Advisers now owns 5,517,611 shares of the company’s stock worth $402,786,000 after purchasing an additional 24,950 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Solventum by 15.3% during the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 307,789 shares of the company’s stock worth $22,469,000 after purchasing an additional 40,812 shares during the last quarter. Finally, Appleton Partners Inc. MA bought a new stake in Solventum during the fourth quarter worth about $7,008,000.

Solventum Stock Performance

NYSE:SOLV opened at $65.78 on Friday. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.23 and a quick ratio of 0.89. The business has a fifty day simple moving average of $70.23 and a two-hundred day simple moving average of $74.86. Solventum has a 1 year low of $62.38 and a 1 year high of $88.20. The company has a market capitalization of $11.41 billion, a P/E ratio of 7.42, a P/E/G ratio of 1.08 and a beta of 0.71.

Solventum (NYSE:SOLV) last released its earnings results on Thursday, February 26th. The company reported $1.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.50 by $0.07. Solventum had a return on equity of 25.26% and a net margin of 18.69%.The business had revenue of $2 billion during the quarter, compared to the consensus estimate of $1.96 billion. During the same period last year, the business posted $1.41 earnings per share. The business’s revenue for the quarter was down 3.7% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. On average, analysts expect that Solventum will post 6.58 earnings per share for the current year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.